# Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies

Source: https://onco.cc/trials/nct04349436/  
OnCo record `nct04349436` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of RP1, intra-tumoral injection, oncolytic virus in merkel cell carcinoma, basal cell carcinoma and cutaneous squamous cell carcinoma, run by Replimune, Inc., active and no longer recruiting.

## Summary

Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies is a phase 1/2 interventional study registered as NCT04349436 by Replimune, Inc., with 69 participants enrolled, started 2020-05-15 and due to reach its primary completion in 2029-07. Interventions recorded: RP1, intra-tumoral injection, oncolytic virus.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04349436
- Phase: 1/2
- Setting: An Open-Label, Multicenter, Phase 1B/2 Study of RP1 in Solid Organ and Hematopoietic Cell Transplant Recipients With Advanced Cutaneous Malignancies (ARTACUS)
- Sponsor: Replimune, Inc.
- Enrolled: 69

## Sources

- ClinicalTrials.gov NCT04349436: https://clinicaltrials.gov/study/NCT04349436

## Connected records

- cancers: [Basal cell carcinoma](https://onco.cc/cancers/basal-cell-carcinoma/), [Cutaneous squamous cell carcinoma](https://onco.cc/cancers/cutaneous-scc/), [Merkel cell carcinoma](https://onco.cc/cancers/merkel-cell-carcinoma/)
- companies: [Replimune](https://onco.cc/companies/replimune/)

---
JSON: https://onco.cc/api/v1/entities/nct04349436.json